Why the decision belongs to the receiving oncology team
Immunotherapy is not one treatment. It describes several approaches that help the immune system act against cancer, and the National Cancer Institute notes that whether it is appropriate depends on the cancer type and individual assessment. That is why no coordinator, and no article, can tell you in advance that a particular Chinese hospital will accept you for immunotherapy or that a specific drug is available to you.
Your current oncologist abroad holds something a remote reviewer does not: the day-to-day picture of how your disease has behaved, how you have tolerated previous treatment, and what has changed recently. The receiving team in China will form its own view from the records you provide. Both perspectives matter, and neither replaces the other.
The practical consequence is that planning should run on two tracks at once. One track is clinical: gathering records and asking whether immunotherapy is a reasonable option for your situation. The other is logistical: understanding what a hospital would need from you, and what you would need from the hospital, before any commitment.
What the receiving hospital needs to see
A Chinese oncology team assessing an overseas patient for immunotherapy generally needs to reconstruct your case from documents. The exact list varies by hospital and by cancer, so treat the following as items to ask the receiving team about rather than a universal checklist.
Pathology is central. The original pathology report, and where relevant the tissue blocks or slides, allow the receiving team to confirm the diagnosis and run or repeat the marker testing that immunotherapy decisions often depend on. If your current hospital already performed such testing, the reports matter as much as the results.
Imaging tells the story of how the disease has changed. Ask your current team which scans best show your current status, and whether they can be shared as files rather than printed films. A short chronological summary of treatments tried, dates, doses, responses and side effects is often more useful to a reviewer than a large unsorted archive.
Your current oncologist's note is valuable, but it is not a referral that obliges a Chinese hospital to accept you. It is one input. The receiving clinicians will decide independently whether immunotherapy is suitable, whether they can offer it, and under what conditions.
- Original pathology report, plus tissue blocks or slides if the receiving team requests them.
- Reports of any marker or genomic testing already done, with the methods used.
- Recent imaging in a shareable format, and the dates of each scan.
- A dated summary of previous treatments and how you responded.
- Current medication list, including anything for side effects or other conditions.
- Contact details for your current oncologist, in case the receiving team wants clarification.
How a records-based opinion fits before travel
A records-based opinion lets a Chinese specialist review your file while you remain at home. It can clarify whether your case is one the hospital would consider for immunotherapy, what further information is missing, and what the next clinical step might be. It cannot confirm that you will be accepted, that a bed will be available, or that a particular agent will be used.
This distinction matters for planning. If the opinion suggests your case is worth pursuing, you can then discuss timing with your current oncologist and decide together whether travel is sensible. If the opinion raises questions, you have learned something useful before spending money on flights.
A proxy consultation is one route to such an opinion and is optional. It is not a prerequisite for every appointment, and an initial enquiry does not require buying one. The free initial case review checks your available diagnosis, records and main question, identifies missing information, and suggests the relevant next step. It is not a diagnosis and not a promise of acceptance.
Decisions to settle before you book anything
Treating travel as the first decision is a planning mistake. It belongs near the end. Before bookings, you need clarity on several points that only the clinical teams can answer.
First, is immunotherapy appropriate for your cancer and current stage, and is it being considered alone or alongside other treatment? Second, what would the receiving hospital need to see before it can give a view? Third, how would your care be shared between the Chinese team and your oncologist abroad, including who manages ongoing prescriptions and monitoring?
Fourth, what is the realistic shape of a visit? Whether a course of treatment can be planned around a single trip, or whether it implies repeated travel, is a clinical and scheduling question for the treating team, not something to assume. Ask them directly, and ask what would happen if your condition changed while you were in China.
Finally, discuss with your current oncologist whether a pause in your present care is acceptable at all. Do not interrupt or alter existing treatment on the basis of an enquiry or a remote opinion. Any change belongs to the clinicians treating you.
Practical support and what to confirm in writing
Once a hospital has indicated it will assess or accept you, coordination becomes concrete. Specialist matching and appointment coordination covers expert matching and appointment-registration requests, with timing and visit preparation. Hospital consultation fees are separate. Hospital, treatment and surgery coordination covers case-specific arrangements with suitable hospitals and senior specialist teams, including admission preparation, after hospital acceptance.
Ask the named hospital what its own written plan or quote includes, rather than relying on general assumptions about what is bundled. Ask whether the visit would be in a standard or international ward, since these are different routes and not everyone uses an international department. Ask what language support is available for consultations and consent discussions.
For practical matters, bilingual hospital navigation and interpretation can be arranged as a separately agreed service. It is coordination, not clinical care. Arrival and local support, including airport pickup and hotel assistance, can be discussed; visa-document assistance can be discussed but no visa outcome can be guaranteed.
Keep a simple file with the hospital's written response, your record list, and the names of the clinicians involved on both sides. If your situation changes, that file is what a new reviewer will need.
Contingencies worth naming early
Planning for immunotherapy abroad should include what happens if the plan does not proceed. The receiving hospital may conclude that immunotherapy is not suitable for you, or that it needs tests you have not yet had, or that it cannot offer treatment within your timeframe. None of these outcomes means the enquiry was wasted.
Ask in advance who to contact if your symptoms worsen before travel. Worsening symptoms need local assessment first; overseas planning should not delay urgent care. Ask what the hospital's process is if you arrive and the treating team's assessment differs from the records-based view. Ask how follow-up would be handled if you return home between cycles.
It also helps to agree with your oncologist abroad what they are willing to do while you are away: review reports, advise on side effects, or coordinate a handover. Their willingness shapes what is realistic.
When you are ready, start with a brief summary through the enquiry form, email or WhatsApp rather than a complete medical archive. The team will explain how to share records after first contact. An initial enquiry is free, and the hospital decides suitability.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.